Oncoinvent ASA: Grant of share options to new CFO

Oncoinvent's board granted incoming CEO Ramzi Amri 5,430,000 share options at a strike price of NOK 0.4671 (VWAP the day before grant); each option converts to one share and Amri holds no shares post-grant. The options are free of consideration, vest 25% after 12 months then monthly (1/36) thereafter, lapse after seven years, and will be adjusted for an approved reverse share split—a standard retention measure with limited immediate market impact but potential future dilution if exercised.

Analysis

Market structure: The CEO option grant (5.43M options at NOK 0.4671) primarily benefits management and aligns incentives toward share-price appreciation; direct dilution risk is real if exercised but is back-loaded (25% at 12 months, remainder vesting monthly) which limits immediate supply shock. Competitive dynamics for Radspherin remain clinical-driven — this grant does not change therapeutic market share or pricing power versus other locoregional alpha therapies, but signals the board expects a multi-year value creation path. Supply/demand for the equity will be driven by trial milestones and news flow (Phase 2 topline) rather than the grant; cross-asset impact is negligible except for sector beta: small-cap biotech risk-off could pressure Oncoinvent and widen CDS spreads and volatility in XBI/IBB.

Risk assessment: Tail risks include a negative Phase 2 readout or unexpected safety/regulatory action (low-probability, high-impact) and radionuclide supply disruption (operational risk) which could vaporize market cap; probability concentrated over next 12–36 months. Immediate (days) effect is likely muted; short-term (weeks–months) volatility will spike around data/IR presentations; long-term (years) depends on approval/commercialization and manufacturing scale. Hidden dependencies: reverse share-split mechanics and outstanding share count are material — a >5–10% prospective dilution threshold would be value-destroying; catalysts are Phase 2 interim reads, CMC/manufacturing supply agreements, and major licensing deals.

Trade implications: Direct play: small, size-controlled long (1–3% notional) in Oncoinvent ahead of clinical catalysts, hedged for sector beta. If you prefer optionality, buy a 12-month call spread (long ATM+10%, short ATM+60%) sized to 0.5–1% notional to cap downside. Pair trade: long ONCO (equity) + short XBI (equal dollar but scaled 0.5x to neutralize sector moves) to isolate company-specific outcome. Avoid large unhedged positions; take profits or cut losses at ±50% intra position move and reduce exposure by 50% if dilution >10% once reverse-split adjusted figures are disclosed.

Key Decisions for Investors

• Establish a disciplined 2% notional long position in Oncoinvent (equity) sized to portfolio, to be held through the next 12–18 months of Phase 2 data cadence; immediately hedge sector beta by shorting XBI equal to 50% of the dollar exposure to cap macro biotech moves.
• If available, buy a 12-month call spread on Oncoinvent (long ~ATM+10%, short ~ATM+60%) sized to 0.5–1% notional to capture upside from positive topline while capping premium; close or roll on +50% or after topline release.
• Reduce or exit long exposure by 50% if company-disclosed post-reverse-split outstanding shares imply option exercise dilution >10% or if cash runway falls below 12 months without committed financing (monitor filings within 30 days of reverse-split effective date).
• Purchase a 3–6 month out-of-the-money protective put (or put structure) equal to 25% position size if a significant regulatory or safety update is expected within 60–90 days; this limits tail downside from a binary negative readout.
• Monitor three specific catalysts over next 90 days before scaling: (1) reverse split adjusted share count and dilution math, (2) any radionuclide supply / manufacturing agreements, and (3) Phase 2 enrollment/interim data timetable — act (size up/down) within 7 trading days of each disclosure.